COMMUNIQUÉS West-GlobeNewswire

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
14/10/2025
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the [...]
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
14/10/2025
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations SALT LAKE CITY, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , ( [...]
R1 to Acquire Phare Health, a Leading AI Platform for Automating Inpatient Coding and Pre-Bill Clinical Documentation Improvement
14/10/2025
Acquisition Expands R1’s Agentic AI Capabilities to Help Providers Unlock Clinical and Financial Value MURRAY, Utah, Oct. 14, 2025 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), an industry leader in managing and [...]
SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months
14/10/2025
42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best [...]
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
14/10/2025
EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
14/10/2025
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
14/10/2025
$50 million drawn down at closing, with access to up to an additional $80 million Strengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC) [...]
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
14/10/2025
First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company’s XTRAC capability to [...]
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
14/10/2025
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on track with established [...]
Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference
14/10/2025
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
FibroBiologics to Present at the 2025 ThinkEquity Conference
14/10/2025
HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
As "Uptober" Ignites Crypto Market, Bonk, Inc. Revs Up Its Revenue-Generating Engine
14/10/2025
Company to Capitalize on its Position as the Most Widely Held Token on Solana and a Historically Strong Q4 for Digital Assets SCOTTSDALE, AZ, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Bonk, Inc. (Nasdaq: BNKK) (the “Company”), [...]
Profound Medical to Participate in the Stifel 2025 Healthcare Conference
14/10/2025
TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, [...]
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
14/10/2025
CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- [...]
Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
14/10/2025
The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support The Company is on Track to Commence the Launch of LIBERTY ® during Q4 This Year HINGHAM, Mass [...]
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
14/10/2025
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice President of Regulatory [...]
Counterpart Health Expands Proven Flywheel for HEDIS Excellence to Third-Party Partners
14/10/2025
Technology platform again powers top-tier HEDIS results for Clover Health Medicare Advantage plans SAN FRANCISCO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of [...]
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
14/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Vireo Growth Inc. Announces Closing of Acquisition of Outstanding Senior Secured Convertible Notes of Schwazze
14/10/2025
– Parties enter into Restructuring Support Agreement; Vireo to bid to acquire control of Schwazze assets – – Schwazze operates 63 dispensaries and 10 manufacturing facilities in Colorado and New Mexico – MINNEAPOLIS, [...]

Pages